Industry

SocialTech Japan Wins First Prize in Social Business Session CHIBA, Japan–(BUSINESS WIRE)–The Asian Entrepreneurship Award 2022 event (AEA2022) was held fully online from Wednesday, October 26th to Thursday, October 27th with the participation of 24 tech startups selected from Asian countries and regions. Among the competing participants, Japan’s OUI Inc., which develops the Smart Eye … [Read more…]

SCHLIEREN, Switzerland & OSAKA, Japan–(BUSINESS WIRE)–Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd (“Ono”). Under the terms of the agreement, MTx will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to … [Read more…]

A new treatment option for severe hypoglycaemia for children and adults living with diabetes Represents Tetris Pharma’s first launch in European Union MARLOW, England–(BUSINESS WIRE)–Tetris Pharma Ltd (“Tetris Pharma” or “the Company”), a subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC), today announces the launch of Ogluo® (glucagon prefilled autoinjector pen) in Germany as … [Read more…]

YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential YH003 in combination with PD-1 are being dosed in phase II multi-regional clinical trials sponsored by Eucure Biopharma for pancreatic cancer and melanoma in Australia, the US and China ISU ABXIS intends to deploy YH003 sequence to develop tri-specific antibody for the treatment of … [Read more…]

YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential. YH003 in combination with PD-1 are being dosed in phase II multi-regional clinical trials sponsored by Eucure Biopharma for pancreatic cancer and melanoma in Australia, the US and China. ISU ABXIS intends to deploy YH003 sequence to develop tri-specific antibody for the treatment of … [Read more…]

Same Facility Revenue Increases 10.2% FRANKLIN, Tenn.–(BUSINESS WIRE)–There was an inadvertent error on the supplementary table titled “Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted Income Attributable to Acadia Healthcare Company, Inc.” on page 11 of the previous release, within the line item titled “Income tax effect of adjustments to income” … [Read more…]

ORM-5029 is a first-in-class drug candidate designed to selectively deliver catalytic GSPT1 protein degraders to HER2-expressing tumor cells via antibody targeting BOSTON & DAEJEON, South Korea–(BUSINESS WIRE)–#ADC—Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the first patient has been dosed with ORM-5029 in a Phase … [Read more…]

PLANO, Texas–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the third quarter ended September 30, 2022, and provide an update on the Company’s business operations and clinical development programs on November 8, 2022, before the U.S. financial … [Read more…]

BURLINGTON, N.C.–(BUSINESS WIRE)–Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on Tuesday, Nov. 8, at 1:25 p.m. PT. A live webcast of the fireside chat will be available via the Labcorp … [Read more…]

OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it has closed the second tranche (the “Second Tranche”) of its previously announced non-brokered … [Read more…]